Search results
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via AOL· 5 days ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 4 days agoModerna experienced a substantial financial shift in the first quarter (Q1) of 2024, reporting a net loss of $1.2bn - a stark contrast to its net income...
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 5 days agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 7 days agoKey Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 5 days agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 5 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via Yahoo Finance· 5 days agoModerna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was ...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 5 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 5 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 5 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.